H POWER

What H POWER does

H POWER (杭州核力欣健生物医药（集团）股份有限公司, Hangzhou Heli Xinjian Biomedical Group) is a vertically integrated Chinese pharmaceutical company founded in 2005 and headquartered in Hangzhou, Zhejiang Province, publicly listed on China's NEEQ (872806). The company focuses on gastroenterology and microecology, with a portfolio spanning probiotics, anti-allergy medications, gastric mucosal protectants, and modernized Traditional Chinese Medicine formulations. Its flagship product, Yijunkang (益君康), is a four-strain live bacteria compound Lactobacillus acidophilus tablet described as China's only such probiotic that does not require refrigeration, holding 12 consecutive years of clinical sales leadership and 30+ years of market presence. The R&D platform spans a 2,000 m² biomedical R&D center in Hangzhou's Zijin Port Life Health Industrial Park with a library of 400+ medical functional bacterial strains, a multi-unit drug delivery innovation technology platform, and a national Class 1 biological new drug in Phase III clinical trials.

The company operates a full industry-chain model of R&D, manufacturing, and commercialization across three sites: Huzhou Manufacturing Base (Phase 1 operational since 2018 with 1.5 billion RMB invested, Phase 2 under construction with 2.5 billion RMB investment for end-2026), Sichuan TCM Manufacturing Base (established 2021 in Ziyang with Drug Production License B certificate), and the Hangzhou R&D center. Revenue is generated through pharmaceutical product sales across prescription/hospital, OTC, and pharmacy chain channels, plus contract manufacturing services having completed 45 product license holder (MAH) transfers for third parties. Go-to-market is sales-led through pharmaceutical sales teams targeting hospitals, pharmacies, and chain drug stores, complemented by deep partnerships with major national pharmacy chains (Da Can Lin, Haiwang Xingchen) under an 'Iron Triangle' brand-terminal-consumer model, experiential marketing at industry conferences (Wuzhen Health Conference, Xipu Conference, Wanzhen Conference), and public welfare health campaigns ('Gut Health China Tour'). The company serves digestive, microecological, anti-allergy, and TCM use cases across consumer, pharmacy, and clinical customer segments in East and Southwest China, with ongoing expansion into women's/children's health and bone/joint therapeutic areas.

Name

H POWER

Legal name

杭州核力欣健生物医药（集团）股份有限公司

Website

https://h-power.biz

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

501–1,000 employees

Short description

H POWER (杭州核力欣健生物医药) is a vertically integrated Chinese pharmaceutical company specializing in gastroenterology and microecology, with a flagship four-strain probiotic (Yijunkang) holding 12 consecutive years of clinical sales leadership, distributed through hospitals, pharmacy chains, and OTC channels across China.

Ownership category

akta.pro rank

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: The company generates revenue through the sale of pharmaceutical products including probiotics, gastrointestinal medications, allergy treatments, and traditional Chinese medicine preparations. Products are sold through both prescription (hospital/pharmacy) and OTC channels.
2. Contract Manufacturing Services: Huzhou manufacturing base provides contract manufacturing services for pharmaceutical products, offering services from clinical samples to commercial production. The company has completed 45 product license holder changes for other companies and conducts entrusted production.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

H POWER (杭州核力欣健生物医药) is a full-chain pharmaceutical enterprise that develops, manufactures, and markets microecological drugs, gastrointestinal medications, anti-allergy products, and modernized Traditional Chinese Medicine preparations. Its flagship product is 益君康 (Yijunkang), China's only four-strain live bacteria probiotic that does not require refrigeration. The company operates three manufacturing bases in Hangzhou, Huzhou, and Sichuan, supporting both proprietary branded products and contract manufacturing services.

Product overview

H POWER (杭州核力欣健生物医药) is a full-chain pharmaceutical enterprise founded in 2005, specializing in gastroenterology and microecology while expanding into women’s/children’s health and bone/joint areas. The product portfolio centers on probiotics (益君康 as flagship four-strain live bacteria product), anti-allergy medications (益力菲, 欣必健), gastrointestinal protectants (益维固), and Traditional Chinese Medicine (植小禾, 壮骨伸筋胶囊, 熄风通络头痛片). The company operates across three manufacturing bases (Huzhou, Hangzhou, Sichuan) with R&D platforms for innovative formulations, biological drugs, and TCM modernization. Core differentiators include China’s only four-strain probiotic not requiring refrigeration and a national Class 1 biological new drug in Phase III clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

• 益君康: 复方嗜酸乳杆菌片 - 国内唯一无需冷藏的四联活菌益生菌产品，用于肠道菌群失调引起的肠功能紊乱。连续12年临床销售第一。
• 益维固
• 益力菲
• 欣必健
• 植小禾
• 欣复益
• 壮骨伸筋胶囊

Products and services

• Yijunkang (益君康) - Compound Lactobacillus Acidophilus Tablets Classic four-strain live bacteria probiotic for treating intestinal flora imbalance and mild acute diarrhea. China's only four-strain probiotic that does not require refrigeration, achieving 12 consecutive years of clinical sales leadership.
• Yiweigu (益维固) - Tepraloxydone Capsules (替普瑞酮胶囊) Gastric mucosal protective agent for treating acute gastritis, chronic gastritis exacerbation (with erosion, bleeding, hyperemia, edema), and gastric ulcers.
• VSL#3 - Compound Lactic Acid Bacteria Powder (复合乳酸菌粉) High-activity compound probiotic powder containing 8 beneficial strains with 450 billion live bacteria per bag.
• Yilifei (益力菲) - Levocetirizine Hydrochloride Oral Solution (盐酸左西替利嗪口服溶液) Anti-allergy medication for treating urticaria, allergic rhinitis, eczema, dermatitis, and pruritic skin conditions.
• Xinbijian (欣必健) - Loratadine Syrup (氯雷他定糖浆) Second-generation antihistamine syrup for relieving allergic rhinitis symptoms including sneezing, runny nose, nasal itching, congestion, and eye itching. Also suitable for chronic urticaria and other allergic skin conditions.
• Zhi Xiao Hu (植小斛) - Sugar-free Xiaochaihu Granules (无蔗糖小柴胡颗粒) Sugar-free Chinese herbal medicine for relieving alternating chills and fever, chest/flank fullness, poor appetite, irritability, bitter mouth, and dry throat associated with Shaoyang syndrome.
• Sugar-free Erding Granules (无蔗糖二丁颗粒) Sugar-free herbal granule for clearing heat and detoxifying, used for heat toxins causing boils, sore throats, and red/painful eyes.
• Sugar-free Orange Half Cough-stop Granules (无蔗糖橘半止咳颗粒) Sugar-free herbal granule for moisturizing lungs, resolving phlegm, relieving cough and asthma, for phlegm-heavy cough with chest stuffiness and throat irritation.
• Xinfuyi (欣复益) - Xifeng Tongluo Headache Tablets (熄风通络头痛片) Chinese patent medicine for treating migraine with liver wind and blood stasis pattern, presenting as throbbing or stabbing headache, commonly in frontal/temporal region, possibly with dizziness and irritability.
• Zhuanggu Shenjin Capsules (壮骨伸筋胶囊) Chinese patent medicine for tonifying liver and kidney, strengthening bones and tendons, for cervical spondylotic radiculopathy with shoulder/arm pain and numbness.
• Contract Manufacturing Services (委托生产服务) Contract pharmaceutical manufacturing services offered through Huzhou and Sichuan manufacturing bases, supporting other companies' products from clinical samples to commercial production across multiple dosage forms. 45 product license holder (MAH) transfers have been completed.

Quantifiable outcome

• 12 consecutive years of clinical sales leadership in China's probiotic category
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Seven partnerships are on record, tiered core, minor and moderate.

• 大参林医药集团股份有限公司 (Da Can Lin Medical Group)coreChannel Partner/ Reseller/ Distributor · 26 April 2026Strategic partnership for co-organization of '益君康·肠道健康中国行' (Gut Health China Tour) public welfare activities. Da Can Lin, as national leading pharmacy chain, provides extensive retail network and digital operations system for product distribution and consumer reach.
• 广东禾润医药有限公司 (Guangdong Herun Pharmaceutical)minorChannel Partner/ Reseller/ Distributor · 26 April 2026Regional pharmaceutical distributor in Guangdong province participating as co-organizer of益君康®肠道健康中国行 (Guangdong station) public welfare roadshow activity in Foshan.
• 海王星辰 (Haiwang Xingchen)coreChannel Partner/ Reseller/ Distributor · 1 April 2026'铁三角' (Iron Triangle) strategic cooperation agreement signed at 2026 Wuzhen Health Conference. Core strategy creates value closed loop between brand owner, chain terminals, and consumers. Haiwang Xingchen brings extensive terminal network and member system; company provides differentiated four-strain no-refrigeration probiotic product.
• 上海智同医药科技有限公司 (Shanghai Zhitong Pharmaceutical Technology Co., Ltd.)coreStrategic or Co-development Partner · 12 November 2025Joint laboratory partnership for multi-unit drug delivery innovation technology platform. The collaboration aims to establish a full value chain from 'technology R&D - achievement transformation - industrial landing'. Lab inauguration ceremony held at Huzhou manufacturing base with officials from South Taihu New District Party Working Committee and Huzhou Market Supervision Administration in attendance.
• 央媒 (Central Media Outlets)moderateGTM or Marketing Partner · 1 January 2025Brand cooperation with central media outlets for public credibility endorsement, brand milestone display, and consumer trust building. Partnership history and key milestones showcased at industry conferences.
• 广东广播电视台新闻频道《品牌广东》栏目 (Guangdong TV News Channel Brand Guangdong Program)minorGTM or Marketing Partner · 1 January 2025Media partner for '益君康·肠道健康中国行' (Guangdong station) public welfare activity, providing media coverage and amplifying activity impact through television journalism.
• 《中国药店》杂志 (China Pharmacy Magazine)moderateGTM or Marketing Partner · 1 January 2025Joint launch of '益生菌金牌推荐官项目' (Probiotic Gold Recommendation Ambassador Project) at 2025万艋会. Project aims to provide systematic training platform for pharmacy staff, professionalizing probiotic product promotion at channel level.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Jiangzhong Pharmaceutical (江中药业): Jiangzhong is a leading Chinese OTC pharmaceutical company specializing in gastrointestinal health (Jiangzhong Jianwei Xiaoshi tablets) and TCM-based consumer health. Most directly comparable to H Power in terms of GI/OTC channel model, pharmacy chain distribution, and China-focused probiotic/TCM portfolio.
• Taiji Group (太极集团): Taiji Group is a major Chinese pharmaceutical manufacturer combining TCM and chemical drug production with significant OTC pharmacy distribution, including GI and microecological products. Comparable in TCM modernization approach and broad OTC channel strategy.
• Jichuan Pharmaceutical (济川药业): Jichuan specializes in digestive and pediatric OTC pharmaceuticals in China, with strong pharmacy chain distribution and a portfolio of TCM-based products. Highly comparable therapeutic focus (GI, pediatrics) and channel-driven model.
• By-Health (汤臣倍健): By-Health is China's largest nutritional supplement company, with a strong probiotic and gut health portfolio sold via pharmacy chains and online. Comparable as a Chinese probiotics-focused brand with similar channel partnerships and consumer-facing marketing approach.
• Health & Happiness (健康元): Health & Happiness is a Chinese pharmaceutical group with a significant digestive and microecological franchise (including the famous 'Bioflor' brand). Directly comparable in microecological drug positioning and China OTC channel strategy.
• Livzon Pharmaceutical Group (丽珠集团): Livzon is a mid-to-large Chinese pharmaceutical company with digestive, anti-infective, and biological drug portfolios, including microecological products. Comparable in diversified pharma structure, R&D pipeline, and China hospital+pharmacy dual channel.
• Sunflower Pharmaceutical (葵花药业): Sunflower is a Chinese pharmaceutical company focused on pediatric, GI, and women's health OTC products distributed primarily through pharmacy chains. Comparable in therapeutic focus, OTC channel strategy, and mid-sized independent pharma profile.

Broad incumbents

• Xiuzheng Pharmaceutical (修正药业): Xiuzheng is one of China's largest privately held OTC pharmaceutical companies with broad TCM and chemical drug portfolios across GI, cardiovascular, and pediatric categories. Comparable as a similarly scaled private Chinese OTC pharma with heavy pharmacy chain presence, but with a much wider portfolio.
• Bayer China Consumer Health: Bayer's Consumer Health division in China includes digestive health brands (e.g., Iberogast, Talcid) and probiotic products. Comparable as a multinational competitor in the Chinese OTC GI/probiotic space, but with significantly broader global scale and resources.
• Hayao Group (哈药集团): Hayao is a large state-affiliated Chinese pharmaceutical group with a broad OTC and nutrition portfolio including probiotic and GI products. Comparable in Chinese pharmacy channel presence, but operates at significantly larger scale across multiple therapeutic areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about H POWER